This article reviews allergen-specific immunotherapy in human and veterinary medicine. Current hypotheses of possible mechanisms of actions are outlined. Indications, success rates, adverse effects and factors influencing outcome of therapy are discussed in humans, dogs, cats and horses.

The classical treatments for dogs with atopic dermatitis have traditionally been oral antipruritic drugs, allergen-specific immunotherapy and topical therapy. Fifty dogs with atopic dermatitis were included in this multicentred, double-blinded, randomized study to compare clinical response to an 8-week period of feeding one of three commercial veterinary foods marketed for dogs with atopic dermatitis (diets A-C) or a widely distributed supermarket food (diet D). Atopic dermatitis was diagnosed using Willemse's criteria and through the exclusion of differential diagnoses. Fourteen dogs were assigned to diet A and 12 dogs each to diet B, C or D. Flea and tick control using a monthly fipronil spot-on product was administered for a minimum of 4 weeks prior to inclusion in the study and during the study period. Evaluations were made monthly. These included lesion scores, using an established scoring system (canine atopic dermatitis extent and severity index, CADESI-03) and owner evaluation of pruritus level using a visual analogue scale. After 8 weeks on the new diets, there was a significant improvement in CADESI and pruritus scores with diet B (Wilcoxon test, P = 0.043 and paired t-test, P = 0.012, respectively), in pruritus scores with diet A (paired t-test, P = 0.019) and in CADESI scores with diet D (Wilcoxon test, P = 0.037). No significant changes were detected with diet C. Based on the results of this study, in addition to the conventional therapies, changing the diet of dogs with atopic dermatitis may be a useful adjunctive therapeutic measure.

Skin physiology in cats has received little attention. The aim of this study was to evaluate the long-term influence of sex, time and the level of dietary fat and energy on the dynamics and qualities of the hair coat. Twenty-four European short-haired laboratory cats were followed over a 1-year period. They were divided into eight groups of three, according to: sex (12 males and 12 females), sexual status (intact or neutered) and diets [(high energy 4300 kcal/kg as fed, 21% fat) vs. (moderate energy 3500 kcal/kg as fed, 10% fat)]. Both diets were fed for 6 months to all cats following a cross-over design. The following parameters were evaluated throughout the study: thickness of hair coat and hair lengths (neck, rump, lateral, flank), hair regrowth (after periodic clippings of 25 cm 2 areas), and telogen/anagen ratio. The thickness of the hair coat initially varied from 1.2-1.7 cm on the neck, 1-1.4 cm on the rump, 1.8-2.5 cm on the flank, and hair shaft lengths were 1.7-2.5, 3.7-3.9 and 2.5-3.2 cm, respectively. Comparison of values revealed few statistical differences: increase of the thickness of hair coat in neutered cats (male and female) during the study, and increase of the length of lateral hairs in all groups during the study. Over all periods and in all groups, the curve of growth was similar (rapid then slower). Some transient variations were attributed to temporary changes in ambient conditions. In conclusion, neither sex, nutrition or season (in housed cats) influenced the general quality of hair coat, in particular hair regrowth. Funding: Royal Canin. Veterinary Dermatology 2004, 15 (Suppl. 1), 41-69 Ó 2004 ESVD and ACVD 41 Poster Abstracts Poster Abstracts

The success rates and adverse effects of a selamectin spot-on preparation, given orally weekly or every other week, against canine generalised demodicosis were evaluated in 44 dogs, 39 with juvenile-onset demodicosis and five with adult-onset demodicosis. The dogs received selamectin at a dose of 24 to 48 mg/kg once a week, or the same dose every two weeks. Thirty-eight dogs completed the study, four dogs were lost to follow-up and two dogs died. Nine dogs went into remission: all had the juvenile-onset form of the disease. There was no difference between the two treatment groups, but dogs with clinical scores of 65 or less responded significantly better than those with a score of over 65 (P=0.0015). The most frequent adverse effects were vomiting and diarrhoea. Two dogs exhibited mild reversible neurological side effects, which resolved with cessation of treatment. Difficulties in oral administration were observed in several dogs.

No abstract